© 1998 by European Society of Cardiology
Copyright © 1998, European Society of Cardiology
Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns
aDivision of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC, USA
bPharmaceutical Division, Novartis, Basel, Switzerland
* Corresponding author. Tel.: +1 (803) 792-2011; Fax: +1 (803) 792-8286.
Background: AT1 receptor activation has been demonstrated to cause increased vascular resistance properties which may be of particular importance in the setting of congestive heart failure (CHF). The overall goal of this study was to examine the effects of ACE inhibition (ACEI) alone, AT1 receptor blockade alone and combined ACEI and AT1 receptor blockade on LV pump function, systemic hemodynamics and regional blood flow patterns in the normal state and with the development of pacing induced CHF, both at rest and with treadmill induced exercise. Methods and results: Pigs (25 kg) were instrumented in order to measure cardiac output (CO), systemic (SVR) and pulmonary vascular (PVR) resistance, neurohormonal system activity, and myocardial blood flow distribution in the conscious state and assigned to one of 4 groups: (1) rapid atrial pacing (240 bpm) for 3 weeks (n=7); (2) ACEI (benazeprilat, 3.75 mg/day) and pacing (n=7); (3) AT1 receptor blockade (valsartan, 60 mg/day) and rapid pacing (n=7); and (4) ACEI and AT1 receptor blockade (benazeprilat/valsartan, 1/60 mg/day, respectively) and pacing (n=7). Measurements were obtained at rest and with treadmill exercise (15°, 3 miles/h; 10 min) in the normal control state and after the completion of the treatment protocols. With rapid pacing, CO was reduced at rest and with exercise compared to controls. ACEI or AT1 blockade normalized CO at rest, but remained lower than control values with exercise. Combination therapy normalized CO both at rest and with exercise. Resting SVR in the CHF group was higher than controls and SVR fell to a similar degree with exercise; all treatment groups reduced resting SVR. With exercise, SVR was reduced from rapid pacing values in the ACEI and combination therapy groups. PVR increased by over 4-fold in the rapid pacing group both at rest and with exercise, and was reduced in all treatment groups. In the combination therapy group, PVR was similar to control values with exercise. Plasma catecholamines and endothelin levels were increased by over 3-fold with chronic rapid pacing, and were reduced in all treatment groups. In the combination therapy group, the relative increase in catecholamines and endothelin with exercise were significantly blunted when compared to rapid pacing only values. LV myocardial blood flow at rest was reduced in the rapid pacing only and monotherapy groups, but was normalized with combination therapy. Conclusion: These findings suggest that with developing CHF, combined ACE inhibition and AT1 receptor blockade improved vascular resistive properties and regional blood flow distribution to a greater degree than that of either treatment alone. Thus, combined ACEI and AT1 receptor blockade may provide unique benefits in the setting of CHF.
KEYWORDS Cardiac output; Myocardial blood flow; Pig; Neurohormone
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. D. McEvoy, M. J. Sabbagh, A. G. Taylor, J. A. Zavadzkas, C. N. Koval, R. E. Stroud, R. L. Ford, J. E. McLean, S. T. Reeves, R. Mukherjee, et al. Aprotinin Modifies Left Ventricular Contractility and Cytokine Release After Ischemia-Reperfusion in a Dose-Dependent Manner in a Murine Model Anesth. Analg., February 1, 2009; 108(2): 399 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O. Phillips, A. Kashani, D. K. Ko, G. Francis, and H. M. Krumholz Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials Arch Intern Med, October 8, 2007; 167(18): 1930 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kostelec, J. Covell, G. D. Buckberg, A. Sadeghi, J. I.E. Hoffman, and G. S. Kassab Myocardial protection in the failing heart: I. Effect of cardioplegia and the beating state under simulated left ventricular restoration J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 875 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Kassab, M. Kostelec, G. D. Buckberg, J. Covell, A. Sadeghi, and J. I.E. Hoffman Myocardial protection in the failing heart: II. Effect of pulsatile cardioplegic perfusion under simulated left ventricular restoration J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 884 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Liu, X.-P. Yang, E. G. Shesely, S. S. Sankey, and O. A. Carretero Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1473 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Nikolaidis, A. Doverspike, R. Huerbin, T. Hentosz, and R. P. Shannon Angiotensin-Converting Enzyme Inhibitors Improve Coronary Flow Reserve in Dilated Cardiomyopathy by a Bradykinin-Mediated, Nitric Oxide-Dependent Mechanism Circulation, June 11, 2002; 105(23): 2785 - 2790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Multani, R. S. Krombach, A. T. Goldberg, M. K. King, J. W. Hendrick, J. A. Sample, S. C. Baicu, C. Joffs, M. deGasparo, and F. G. Spinale Myocardial Bradykinin Following Acute Angiotensin-Converting Enzyme Inhibition, AT1 Receptor Blockade, or Combined Inhibition in Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 369 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Schulz and G. Heusch Review: AT 1-receptor blockade in experimental myocardial ischaemia/reperfusion Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S136 - S140. [PDF]
|
|
|
|
|
|
D. Lebeche, Zhao Bin Kang, and R. Hajjar Candesartan abrogates G protein-coupled receptors agonist-induced MAPK activation and cardiac myocyte hypertrophy Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S154 - S161. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Kawai, S. Y. Stevens, and C.-S. Liang Renin-angiotensin system inhibition on noradrenergic nerve terminal function in pacing-induced heart failure Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H3012 - H3019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S Weinberg, A. J Weinberg, and D. H Zappe Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 217 - 233. [PDF]
|
|
|
|
 |
|
 M. J. Clair, M. K. King, A. T. Goldberg, J. W. Hendrick, R. Nisato, D. M. Gay, A. E. Morrison, J. H. McElmurray III, R. S. Krombach, B. R. Bond, et al. Selective Vasopressin, Angiotensin II, or Dual Receptor Blockade with Developing Congestive Heart Failure J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 852 - 860. [Abstract] [Full Text]
|
|
|
|
|
|
L. A.M. Zornoff, S. A.R. Paiva, B. B. Matsubara, L. S. Matsubara, and J. Spadaro Combination Therapy with Angiotensin Converting Enzyme Inhibition and AT1 Receptor Inhibitor on Ventricular Remodeling After Myocardial Infarction in Rats Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 203 - 209. [Abstract] [PDF]
|
|